4.7 Article

Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice

Journal

LIVER INTERNATIONAL
Volume 40, Issue 6, Pages 1366-1377

Publisher

WILEY
DOI: 10.1111/liv.14423

Keywords

bile acid metabolism; FXR signaling; PPAR alpha signaling

Funding

  1. Austrian Science Foundation [F3517-B20, F3008-B05, F7310-B21]

Ask authors/readers for more resources

Background Bile acids (BAs) regulate hepatic lipid metabolism and inflammation. Bile salt export pump (BSEP) KO mice are metabolically preconditioned with a hydrophilic BA composition protecting them from cholestasis. We hypothesize that changes in hepatic BA profile and subsequent changes in BA signalling may critically determine the susceptibility to steatohepatitis. Methods Wild-type (WT) and BSEP KO mice were challenged with methionine choline-deficient (MCD) diet to induce steatohepatitis. Serum biochemistry, lipid profiling as well as intestinal lipid absorption were assessed. Markers of inflammation, fibrosis, lipid and BA metabolism were analysed. Hepatic and faecal BA profile as well as serum levels of the BA synthesis intermediate 7-hydroxy-4-cholesten-3-one (C4) were also investigated. Results Bile salt export pump KO MCD-fed mice developed less steatosis but more inflammation than WT mice. Intestinal neutral lipid levels were reduced in BSEP KO mice at baseline and under MCD conditions. Faecal non-esterified fatty acid concentrations at baseline and under MCD diet were markedly elevated in BSEP KO compared to WT mice. Serum liver enzymes and hepatic expression of inflammatory markers were increased in MCD-fed BSEP KO animals. PPAR alpha protein levels were reduced in BSEP KO mice. Accordingly, PPAR alpha downstream targets Fabp1 and Fatp5 were repressed, while NF kappa B subunits were increased in MCD-fed BSEP KO mice. Farnesoid X receptor (FXR) protein levels were reduced in MCD-fed BSEP KO vs WT mice. Hepatic BA profile revealed elevated levels of T beta MCA, exerting FXR antagonistic action, while concentrations of TCA (FXR agonistic function) were reduced. Conclusion Presence of hydroxylated BAs result in increased faecal FA excretion and reduced hepatic lipid accumulation. This aggravates development of MCD diet-induced hepatitis potentially by decreasing FXR and PPAR alpha signalling.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis

Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, David Bauer, Rafael Paternostro, Lorenz Balcar, Benedikt Hofer, Nikolaus Pfisterer, Michael Schwarz, Bernhard Scheiner, Albert F. Staettermayer, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger

Summary: In this study, it was found that carvedilol is more effective than propranolol in the secondary prophylaxis of variceal bleeding, as it induces more significant reductions in hepatic venous pressure gradient (HVPG) and is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC

Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley

Summary: In this 96-week open-label extension study, Cilofexor was found to be safe and effective in improving liver function and biomarkers of cholestasis and cellular injury in patients with PSC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Julie Lin, Wen-Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin

Summary: This study evaluated IL-31 as a potential biomarker for pruritus in clinical trials of cilofexor, an FXR agonist, in patients with cholestatic liver diseases. IL-31 levels were found to be elevated in patients with PSC and PBC and correlated with serum bile acids. The study also showed that cilofexor therapy increased IL-31 levels in patients with NASH.

HEPATOLOGY (2023)

Letter Medical Laboratory Technology

Lot-to-lot reagent changes and commutability of quality testing materials for total bile acid measurements

Corey Markus, Suzette Coat, Hanns-Ulrich Marschall, Susan Matthews, Tze Ping Loh, Wayne Rankin, William M. M. Hague

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Gastroenterology & Hepatology

Comparison of adenoma detection rate and proximal serrated polyp detection rate and their effect on post-colonoscopy colorectal cancer mortality in screening patients

Jasmin Zessner-Spitzenberg, Elisabeth Waldmann, Lena Jiricka, Lisa-Maria Rockenbauer, Anna Hinterberger, Jeremy Cook, Arno Asaturi, Aleksandra Szymanska, Barbara Majcher, Michael Trauner, Monika Ferlitsch

Summary: This study investigated the association of proximal serrated polyp detection rate (PSDR) and adenoma detection rate (ADR) with post-colonoscopy colorectal cancer (PCCRC) death. The results showed that both ADR and PSDR were significantly associated with PCCRC death. Therefore, striving for a high PSDR in addition to a high ADR may reduce the risk of PCCRC mortality in patients undergoing screening colonoscopy.

ENDOSCOPY (2023)

Article Gastroenterology & Hepatology

Polyp characteristics at screening colonoscopy and post- colonoscopy colorectal cancer mortality: a retrospective cohort study

Jasmin Zessner-Spitzenberg, Lena Jiricka, Elisabeth Waldmann, Lisa -Maria Rockenbauer, Jeremy Cook, Anna Hinterberger, Barbara Majcher, Aleksandra Szymanska, Arno Asaturi, Michael Trauner, Monika Ferlitsch

Summary: A retrospective study with 316,001 individuals revealed that polyps sized 10-20mm and high-grade dysplasia are significantly associated with post-colonoscopy colorectal cancer (PCCRC) mortality. Patients with polyps <10mm and without high-grade dysplasia have significantly lower PCCRC mortality compared to the general population, while those with polyps >10mm or with high-grade dysplasia do not have this advantage.

GASTROINTESTINAL ENDOSCOPY (2023)

Article Infectious Diseases

Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates

David Chromy, David Bauer, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, Philipp Schwabl, Teresa Binter, Lisa Steininger, Caroline Schwarz, Armin Rieger, Katharina Grabmeier-Pfistershammer, Michael Trauner, Peter Ferenci, Markus Peck-Radosavljevic, Mattias Mandorfer, Thomas Reiberger

Summary: HCV cure rates in Viennese HIV patients increased significantly from 49% in the IFN era to 88-95% in the DAA era. However, MSM-related risk behavior and reinfections have become the key challenges towards HCV elimination in HIV/HCV-coinfected patients.

INFECTIOUS DISEASES (2023)

Article Oncology

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinomada European multicenter cohort

K. Pomej, L. Balcar, K. Shmanko, S. Welland, V. Himmelsbach, B. Scheiner, A. Mahyera, B. Mozayani, M. Trauner, F. Finkelmeier, A. Weinmann, A. Vogel, M. Pinter

Summary: There is no consensus on the optimal systemic treatment regimen for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients. This European multicenter study analyzed the clinical characteristics and outcomes of cHCC-CCA patients, focusing on those receiving palliative systemic therapy, including immune checkpoint inhibitors (ICIs). The study found no significant difference in overall survival, progression-free survival, overall response rate, and disease control rate between patients receiving cytotoxic chemotherapy (CHT) and non-cytotoxic chemotherapy (nCHT).

ESMO OPEN (2023)

Article Gastroenterology & Hepatology

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreone, Stuart C. Gordon, Christopher L. Bowlus, Eric J. Lawitz, Richard J. Aspinall, Daniel S. Pratt, Karina Raikhelson, Maria S. Gonzalez-Huezo, Michael A. Heneghan, Sook-Hyang Jeong, Alma L. Ladron de Guevara, Marlyn J. Mayo, George N. Dalekos, Joost P. H. Drenth, Ewa Janczewska, Barbara A. Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J. Trivedi, Lisa Forman, David E. J. Jones, Stephen D. Ryder, Mark G. Swain, Alexandra Steinberg, Pol F. Boudes, Yun-Jung Choi, Charles A. McWherter

Summary: This study evaluated the efficacy and safety of seladelpar in patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid. The results showed that seladelpar significantly improved liver biochemistry and pruritus in these patients, and it was well tolerated.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

Grazia Pennisi, Marco Enea, Vincenzo Falco, Guruprasad P. Aithal, Naaventhan Palaniyappan, Yusuf Yilmaz, Jerome Boursier, Christophe Cassinotto, Victor de Ledinghen, Wah Kheong Chan, Sanjiv Mahadeva, Peter Eddowes, Philip Newsome, Thomas Karlas, Johannes Wiegand, Vincent Wai-Sun Wong, Joern M. Schattenberg, Christian Labenz, Won Kim, Myoung Seok Lee, Monica Lupsor-Platon, Jeremy F. L. Cobbold, Jian-Gao Fan, Feng Shen, Katharina Staufer, Michael Trauner, Rudolf Stauber, Atsushi Nakajima, Masato Yoneda, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Ming-Hua Zheng, Calogero Camma, Quentin M. Anstee, Ferenc E. Mozes, Michael Pavlides, Salvatore Petta

Summary: This study evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The results showed that liver stiffness measurement (LSM) and AGILE 3+ were better at determining advanced fibrosis compared to serum tests. The evaluation of diagnostic methods for NAFLD with T2D is clinically significant.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, Quentin M. Anstee, Juan Pablo Arab, Marco Arrese, Ramon Bataller, Ulrich Beuers, Jerome Boursier, Elisabetta Bugianesi, Christopher D. Byrne, Graciela E. Castro Narro, Abhijit Chowdhury, Helena Cortez-Pinto, Donna R. Cryer, Kenneth Cusi, Mohamed El-Kassas, Samuel Klein, Wayne Eskridge, Jiangao Fan, Samer Gawrieh, Cynthia D. Guy, Stephen A. Harrison, Seung Up Kim, Bart G. Koot, Marko Korenjak, Kris V. Kowdley, Florence Lacaille, Rohit Loomba, Robert Mitchell-Thain, Timothy R. Morgan, Elisabeth E. Powell, Michael Roden, Manuel Romero-Gomez, Marcelo Silva, Shivaram Prasad Singh, Silvia C. Sookoian, C. Wendy Spearman, Dina Tiniakos, Luca Valenti, Miriam B. Vos, Vincent Wai-Sun Wong, Stavra Xanthakos, Yusuf Yilmaz, Zobair Younossi, Ansley Hobbs, Marcela Villota-Rivas, Philip N. Newsome

Summary: This study aimed to determine if there was a need to change the nomenclature and definition of NAFLD and NASH. Through a Delphi process involving content experts and patient advocates, a consensus was reached to replace NAFLD with metabolic dysfunction-associated steatotic liver disease (MetALD) and modify the diagnostic criteria. The new nomenclature and criteria are widely supported, nonstigmatizing, and can improve awareness and patient identification.

HEPATOLOGY (2023)

Article Multidisciplinary Sciences

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients

Lorenz Balcar, David Bauer, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter

Summary: Immunotherapy is the new standard of care for hepatocellular carcinoma, but there is a need for biomarkers that predict treatment response and survival. This study suggests that the relative change in IgG after ICI treatment can serve as a negative prognostic marker in patients with HCC.

PLOS ONE (2023)

Article Gastroenterology & Hepatology

Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity

Tomas Machacek, Claudia D. Fuchs, Franziska Winkelmann, Marcus Frank, Hubert Scharnagl, Tatjana Stojakovic, Martina Sombetzki, Michael Trauner

Summary: In this study, the researchers evaluated the effect of polyhydroxylated bile acids (BAs) on the inflammation and fibrosis caused by Schistosoma mansoni infection. They found that mice lacking the Bsep gene showed less hepatic inflammation and fibrosis after infection, which could be attributed to the changes in bile acid composition and blood pH resulting from the loss of Bsep gene, affecting parasite fecundity and thus attenuating the development of S. mansoni-induced hepatic inflammation and fibrosis.

LIVER INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy

Bernhard Scheiner, Katharina Lampichler, Katharina Pomej, Lucian Beer, Lorenz Balcar, Riccardo Sartoris, Mohamed Bouattour, Sabrina Sidali, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Martina Scharitzer, Dietmar Tamandl, David J. Pinato, Maxime Ronot, Matthias Pinter

Summary: This study evaluated the prognostic and predictive value of baseline transversal psoas muscle thickness (TPMT) measurement in patients with hepatocellular carcinoma (HCC) undergoing immunotherapy. The results showed that patients with sarcopenia had a poorer prognosis and a lower response to immunotherapy.

HEPATOLOGY COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling

Claudia D. Fuchs, Thierry Claudel, Veronika Mlitz, Alessandra Riva, Moritz Menz, Ksenia Brusilovskaya, Felix Haller, Maximilian Baumgartner, Philipp Koenigshofer, Lukas W. Unger, Wilhelm Sjoeland, Hubert Scharnagl, Tatjana Stojakovic, Georg Busslinger, Thomas Reiberger, Hanns-Ulrich Marschall, Michael Trauner

Summary: The GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in a mouse model of sclerosing cholangitis. GLP-2 treatment decreases hepatic inflammation and fibrosis, and activates the intestinal FXR-FGF15/19 signaling axis, resulting in reduced expression of Cyp7a1 and increased expression of Cyp2c70 in the liver, contributing to its protective effects.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2023)

No Data Available